EDU 26 - At a Crossroads: A Multidisciplinary Perspective on the Management of Esophageal Adenocarcinoma
MODERATOR(S)
Julie Koenig, MD - Mass General Brigham
session DESCRIPTION
Recent trial results have sparked a paradigm shift in the management of esophageal and gastroesophageal junction adenocarcinomas, with many centers moving toward perioperative chemotherapy and away from neoadjuvant chemoradiotherapy. This shift has led to declining radiation oncology referrals for adenocarcinoma, yet the optimal management remains a subject of intense multi-disciplinary debate. This "Tumor Board" style session brings together radiation oncologists, medical oncologists, and surgeons to challenge current practice patterns and dissect the latest evidence to optimize neoadjuvant therapy, including topics such as selecting patients for non operative management and integrating advances in systemic therapy including immunotherapy.
learning objectives
- To compare current neoadjuvant strategies and define the role of radiotherapy in management in esophageal adenocarcinomas.
- Evaluate evidence-based criteria for organ preservation to identify ideal candidates for a safe and effective "Watch and Wait" approach in esophageal cancer.
- Discuss how advances in systemic therapy including immunotherapy fits into various neoadjuvant strategies and may facilitate NOM and discusses trial designs to guide clinical decision making in this area.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
03:00pm - 03:02pm ETSpeaker: Julie Koenig, MD - Mass General Brigham, Somerville
-
03:02pm - 03:17pm ETSpeaker: Thomas Holden, MD - Department of Medicine, Stanford University School of Medicine, Palo Alto
-
03:17pm - 03:32pm ETSpeaker: Karyn Goodman, MD, MS, FASTRO - Icahn School of Medicine at Mount Sinai, New York
-
03:32pm - 03:47pm ETSpeaker: Stephanie Worrell, - University of Arizona, Tucson
-
03:47pm - 04:00pm ETSpeaker: Julie Koenig, MD - Mass General Brigham, Somerville